Figure 7
Projected impact of antiviral therapy on SARS-CoV-2 effective reproductive number (Re). Each line in each panel is based on simulations of 3000 transmitters with varying daily exposure contacts. Panels (A–C) assume early symptomatic therapy (before peak viremia, within ~ 5 days after exposure) with 100% efficacy. Panels (D–F) assume post-exposure prophylaxis given during pre-symptomatic infection with different efficacies (colored lines). (A and D) Projected Re given different amounts of antiviral uptake in the population, (B and E) Projected percent of infected people who infect at least one person given different amounts of antiviral uptake in the population. (C and F) Projected percent of infected people who infect at least 5 people given different amounts of antiviral uptake in the population. (G) Projected impact of post-exposure prophylaxis on SARS-CoV-2 reproductive number according to the day of treatment relative to exposure with different percentages of infected individuals receiving antiviral therapy.
